** Shares of Innovent Biologics 1801.HK climb 3.2% to HK$36.65, on track for the biggest one-day pct rise since Dec. 9

** Innovent Biologics says China's National Medical Products Administration (NMPA) has approved second New Drug Application (NDA) of DOVBLERON, which is an oral ROS1 inhibitor for treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer

** Says the NDA was accepted by the U.S. Food and Drug Administration for priority review in December 2024

** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both gain 0.4% while Hang Seng Index .HSI adds 0.2%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))